Drug intelligence / Profile preview

phSC-Hhom-4

Development stage: Unknown
Lead developer: International Stem Cell Corporation
Modality: Stem Cell Therapies → Cell Therapies
Administration: Injection

Overview

phSC-Hhom-4 is a human parthenogenetic homozygous stem cell line developed by International Stem Cell Corporation (ISCO). It is derived from unfertilized human eggs through a process called parthenogenesis, which results in pluripotent stem cells. As a homozygous line, it carries a single set of HLA (Human Leukocyte Antigen) genes, which allows it to be immunologically compatible with a significant percentage of the human population. This "HLA-matching" strategy is designed to minimize immune rejection following transplantation, potentially serving as a universal or semi-universal source for various cell-based therapies, such as those for Parkinson's disease, liver disease, or retinal disorders.

Other names: Parthenogenetic homozygous stem cell line 4

Beyond the preview

Go deeper on phSC-Hhom-4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on phSC-Hhom-4.

Explore the full profile